Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）

• Status: Recruiting
• Trial end date: 2021-11-30
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the efficacy and safety of Anlotinib following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Anhui Shi, MD
• Collaborators: Beijing Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Criteria

Inclusion Criteria:

• 1.Age at least 18 years.

• 2.Documented evidence of NSCLC (locally advanced, unresectable, Stage III).

• 3.Patients must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy.

• 4.ECOG PS : 0 to 1.

• 5.Estimated life expectancy of more than 12 weeks.

Exclusion Criteria:

• 1.Prior exposure to any anti-angiogenesis drugs.

• 2.Central lung carcinoma along with large vessels or tumor with cavum or necrosis.

• 3.Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.

• 4.Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy.

• 5.Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or COPD.